Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Arrow Japan to Diversify Business from Critical Care Products
November 18, 2002
- Terumo: Sales Up 3.4% in Japan, 8.1% Overseas
November 18, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 18, 2002
- OTC NEWS IN BRIEF
November 18, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 18, 2002
- WEBSITE NEWS
November 11, 2002
- Researcher-led Clinical Trials on Anticancer Agents by NPO Introduced
November 11, 2002
- BUSINESS NEWS IN BRIEF
November 11, 2002
- CRCs Should Report All Events: SMO Seminar
November 11, 2002
- Fujisawa: Record-high Sales, Profits in 1st Half of FY2002 Marked
November 11, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 11, 2002
- Major Wholesalers' 1st-half Sales Unexpectedly Good
November 11, 2002
- Meiji Seika, Bayer to Comarket Bayclear Plus
November 11, 2002
- Freund: Sales Up 1.9%, Operating Profits Down 41.2%
November 11, 2002
- GSK, Block Drug Company (Japan) Integrated on November 1
November 11, 2002
- Health Minister Determines to Set Up Better Healthcare System
November 11, 2002
- Kuraya Sanseido Takes Over OTC Business from Heisei Yakuhin
November 11, 2002
- Korosho to Prepare Comprehensive GL for Clinical Trials
November 11, 2002
- Council to Issue Supplements QC Verification Seals
November 11, 2002
- Dear-Doctor Letter for Edaravone Issued
November 11, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…